Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Rhea-AI Summary

Boundless Bio (Nasdaq: BOLD) announced a poster presentation at the AACR‑NCI‑EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 22–26, 2025 in Boston, MA. The poster, titled "Synergistic oral combination of selective RNR inhibitor BBI‑825 with selective CHK1 inhibitor BBI‑355 targets unique dependencies of oncogene amplified cancers", is Abstract Number LB‑A022 in Poster Session A.

The session is scheduled for Thursday, October 23, 2025, 12:30–4:00 PM ET at Level 2, Exhibit Hall D.

SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Boundless Bio, (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced an upcoming poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 22-26, 2025 in Boston, MA.

Details of the presentations are as follows:

Title: Synergistic oral combination of selective RNR inhibitor BBI-825 with selective CHK1 inhibitor BBI-355 targets unique dependencies of oncogene amplified cancers
Abstract Number: LB-A022
Session: Poster Session A
Session Date and Time: Thursday October 23, 2025, 12:30-4:00 PM ET
Location: Level 2, Exhibit Hall D

About Boundless Bio

Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors. Boundless Bio’s research focuses on extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14% to 17% of cancer patients. Boundless Bio is developing the first ecDNA-directed therapeutic candidates (ecDTx), BBI-355, an oral, selective inhibitor of checkpoint kinase 1 (CHK1), and BBI-825, an oral, selective inhibitor of ribonucleotide reductase (RNR). These compounds are being evaluated in combination in patients with oncogene amplified cancers in the Company’s phase 1/2 POTENTIATE clinical trial. Boundless Bio is conducting IND-enabling studies of another ecDTx, BBI-940, a potentially first-in-class orally bioavailable, selective Kinesin degrader. Boundless Bio is headquartered in San Diego, CA.

For more information, visit www.boundlessbio.com and follow us on LinkedIn and X.

Investor Contacts:
James Lee, Boundless Bio, Inc.
jlee@boundlessbio.com

Renee Leck, THRUST Strategic Communications
renee@thrustsc.com

Media Contact:
Carly Scaduto
carly@thrustsc.com

FAQ

When will Boundless Bio (BOLD) present at the AACR‑NCI‑EORTC conference in 2025?

Boundless Bio will present on October 23, 2025 during Poster Session A from 12:30–4:00 PM ET.

What is the title of Boundless Bio's (BOLD) poster and its abstract number?

The poster is titled "Synergistic oral combination of selective RNR inhibitor BBI‑825 with selective CHK1 inhibitor BBI‑355…" and is Abstract Number LB‑A022.

Where can attendees find Boundless Bio's (BOLD) poster at the conference?

The poster will be located on Level 2, Exhibit Hall D during Poster Session A on October 23, 2025.

Which Boundless Bio compounds are featured in the October 23, 2025 poster (BOLD)?

The poster describes a combination of BBI‑825 (selective RNR inhibitor) with BBI‑355 (selective CHK1 inhibitor).

What cancer biology focus does Boundless Bio's (BOLD) poster address at the 2025 meeting?

The poster targets dependencies of oncogene amplified cancers, informed by extrachromosomal DNA (ecDNA) biology.